Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Shih

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Blood|June 8, 2017
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical responseMichael D Amatangelo, Lynn Quek, Alan Shih, et al.
Cancer Cell|July 5, 2011
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformationKelly Moran-Crusio, Linsey Reavie, Alan Shih, et al.
Nature Medicine|July 18, 2018
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenibLynn Quek, Muriel D David, Alison Kennedy, et al.
Cancer Cell|December 7, 2010
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiationMaria E Figueroa, Omar Abdel-Wahab, Chao Lu, et al.
Cell Reports|December 9, 2014
DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemiaRaajit Rampal, Altuna Alkalin, Jozef Madzo, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcomaBettina Nadorp, Audrey Lasry, Sanam Loghavi, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Blood|June 8, 2017
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical responseMichael D Amatangelo, Lynn Quek, Alan Shih, et al.
Cancer Cell|July 5, 2011
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformationKelly Moran-Crusio, Linsey Reavie, Alan Shih, et al.
Nature Medicine|July 18, 2018
Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenibLynn Quek, Muriel D David, Alison Kennedy, et al.
Cancer Cell|December 7, 2010
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiationMaria E Figueroa, Omar Abdel-Wahab, Chao Lu, et al.
Cell Reports|December 9, 2014
DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemiaRaajit Rampal, Altuna Alkalin, Jozef Madzo, et al.
Biorxiv : the Preprint Server for Biology|January 23, 2026
Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcomaBettina Nadorp, Audrey Lasry, Sanam Loghavi, et al.
Pageof 2